Celldex declines as it abandons barzolvolimab in atopic dermatitis
FROM THE WIRE · SEEKINGALPHA.COM
[Allergic Reaction From Atopic] aquaArts studio/iStock via Getty Images * Celldex (CLDX [https://seekingalpha.com/symbol/CLDX]) is down ~2% in after-hours trading Thursday after reporting that a phase 2 trial of barzolvolimab for atopic dermatitis missed its primary and…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA failed phase 2 trial weighs on the stock, while the program continues in phase 3 for urticaria.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The stock is down about 2% in after-hours trading.
- 02The phase 2 trial missed its primary and secondary endpoints.
- 03Barzolvolimab remains in phase 3 for chronic spontaneous urticaria.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets